A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.

NPJ Prim Care Respir Med · 2016 · PMC5122307 · PMID 27883002

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Asthma patients In all three substudies, after reading the PIL only, fewer patients had at least one critical error using the ELLIPTA inhaler, albeit only statistically significant when compared with Turbuhaler, and borderline significant when compared with MDI ( Figure 1b ; Table 3B ).

also in 11,409 other papers

a nonsignificant trendno p-value reported

For asthma patients, the proportion making at least one critical error or overall error after reading the PIL was significantly lower with the ELLIPTA inhaler compared with the Turbuhaler with a nonsignificant trend for ELLIPTA compared with DISKUS and MDI.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.